Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-08
2005-03-08
Richter, Johann (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S360000, C544S364000
Reexamination Certificate
active
06864261
ABSTRACT:
A compound of formula(wherein A, R1, R2, R6, m and n are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Piperazine Compound”); pharmaceutical compositions comprising a Piperazine Compound; and methods for treating pain, urinary incontinence (UI), an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia and depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.
REFERENCES:
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5762925 (1998-06-01), Sagen
patent: 5922872 (1999-07-01), Cook et al.
patent: 6109269 (2000-08-01), Rise et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: WO 9937304 (1999-07-01), None
patent: WO 0208221 (2002-01-01), None
patent: WO 0216318 (2002-02-01), None
patent: WO 02072536 (2002-09-01), None
patent: WO 02076946 (2002-10-01), None
patent: WO 02076946 (2002-10-01), None
Berkow et al., “The Merck Manual of Medical Information,” pp. 345-350, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 352-355, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 496-500, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 528-530, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 530-532, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 631-634, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 525-526, 1997.
Chiamulera et al., “Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Rice,” Nature Neuroscience 4(9):873-874(2001).
Cooke, “Glycopyrrolate in Bladder Dysfunction,” SA Medical Journal, 63:3 (1983).
Di Marzo et al., “Endovanilloid Signaling in Pain,” Current Opinion in Neurobiology 12:372-379 (2002).
Dogrul et al., Peripheral and Spinal Antihyperalgesic activity of SIB-1757, a Metabotropic glutamate receptor (mGLUR5) Antagonist, in Experimental Neuropathic Pain in Rats, Neuroscience Letters 292(2):115-118 (2000).
Foley, “Pain” Cecil Textbook of Medicine, pp. 100-107 (1996).
Fundytus et al, “Antisense Oligonucleotide Knockdown of mGluR1Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation,” Pharmacology, Biochemistry & Behavior 73:401-410 (2002).
Fundytus et al., “In vivo Antinociceptive activity of Anti-Rat mGluR1and mGluR5Antibodies in Rats,” NeuroReport 9:731-735 (1998).
Fundytus et al., “Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR1) Alleviates Pain and Restores Opioid Efficacy after Nerve Injury in Rats,” British Journal of Pharmacology 132:354-367 (2001).
Fundytus et al., “Effect of Activity at Metabotropic, as well as Ionotropic (NMDA), Glutamate Receptors on Morphine Dependence,” British Journal of Pharmacology 113:1215-20 (1994).
Fundytus, “Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain,” CNS Drugs 15:29-58, (2001).
Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506, 901-915 (L. Brunton, author; J. Hardman and L. Limbird eds., 9thed. 1996).
Herzog et al., “Urinary Incontinenece: Medical and Psychosocial Aspects,” Annu. Rev. Gerontol. Geriatr. 9:74-119, (1989).
Jhamandas et al., “Spinal Amino Acid Release and Precipitated Withdrawal in Rats Chronically Infused with Spinal Morphine,” The Journal of Neuroscience 16(8):2758-66 (Apr. 15, 1996).
Levin et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder,” The Journal of Urology, 128:396-398 (1982).
Mirakur et al., “Glycopyrrolate: Pharmacology and Clinical use,” Anaesthesia 38:1195-1204 (1983).
Ossowska et al., “Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) produces antiparkinsonian-Like Effects in Rats,” Neuropharmacology 41:413-420 (2001).
Resnick, “Urinary Incontinence,” Lancet 346:94-99 (1995).
Sharif et al., “Attenuation of Morphine Tolerance after Antisense Oligonucleotide Knock-Down of Spinal mGluR1, ” British Journal of Pharmacology 136:865-72 (2002).
Spooren et al., “Novel Allosteric Antagonists Shed Light on Receptors and CNS Disorders,” Trends in Pharmacological Sciences, 22(7):331-337 (2001).
Tatarczynska et al., Potential anxiolytic- and Antidepressant-Like Effects of MPEP, a Potent, Selective and Systemically Active mGlu5 Receptor Antagonist, British Journal of Pharmacology 132(7):1423-1430 (2001).
Walker et al., “Metabotropic Glutamate Receptor Subtype 5 (mGlu5) and Nociceptive Function. I. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain,” Neuropharmacology 40:1-9 (2001).
Wein, “Pharmacology of Incontinence,” Urologic Clinics of North America, 22(3):557-577 (1995).
Bartho et al., “Involvement of Capsaicin-Sensitive Neurones in Hyperalgesia and Enhanced Opioid Antinociception in Inflammation,” Naunyn-Schmiedeberg's Archives of Pharmacology, 342:666-670 (1990).
D'Amour et al., “A Method for Determining Loss of Pain Sensation,” J. Pharmacol. Exp. Ther. 72:74-79 (1941).
Hargreaves et al., “A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia,” Pain 32(1):77-88 (1988).
Kim, “An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat,” Pain 50(3):355-363 (1992).
Masu et al., “,” Nature, 349:760-765 (1991).
Miller et al., “,” The Journal of Neuroscience 15(9):6103-6109 (1995).
Schlaeger et al., “,” New Dev. Appl. Anim. Cell Techn., Proc. ESACT Meet., 15th(1998), 105-112 and 117-120.
Seltzer et al., “A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury,” Pain 43:205-218 (1990).
Stein, “Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds,” Pharmacology Biochemistry and Behavior 31:451-455 (1988).
Treit, “Animal Models for the Study of Anti-Anxiety Agents: A Review,” Neuroscience & Biobehavioral Reviews 9(2):203-222 (1985).
Gharagozloo Parviz
Islam Khondaker
Kyle Donald J.
Sun Qun
Tafesse Laykea
Euro-Celtique S.A.
Jones Day
Richter Johann
Sackey Ebenezer
LandOfFree
Therapeutic agents useful for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents useful for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents useful for treating pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3370575